A major international study suggests that a simple blood test measuring a specific biological marker associated with Alzheimer’s disease could help identify older adults at increased risk of developing cognitive impairment up to a decade before noticeable symptoms emerge.
The research, led by scientists at the Mass General Brigham Neuroscience Institute in the United States, represents an important step toward understanding how blood-based biomarkers may improve the early identification of Alzheimer’s-related cognitive decline.
The findings were presented at the Alzheimer’s Association International Conference (AAIC) 2026 and simultaneously published in the prestigious medical journal JAMA.
A Promising Biomarker for Early Risk Assessment
The study focused on phosphorylated tau 217 (p-tau217), a form of the tau protein associated with biological changes linked to Alzheimer’s disease.
Abnormal changes involving tau proteins and the accumulation of amyloid-beta plaques are among the key characteristics of Alzheimer’s disease. These pathological processes can begin many years before individuals experience memory problems or other noticeable cognitive symptoms.
By measuring p-tau217 levels in blood samples, researchers aimed to determine whether this biomarker could help estimate the likelihood of future cognitive impairment among people who were cognitively healthy at the beginning of the study.
The international research included 2,684 older adults without cognitive impairment at baseline. Data were combined from six observational studies and clinical trials conducted across North America, Japan, and Australia.
Participants were monitored for varying periods, with a median follow-up of approximately 5.4 years and a maximum follow-up of 13.5 years.
Significant Findings Over Five and Ten Years
The results demonstrated a strong association between elevated blood p-tau217 levels and an increased risk of developing cognitive impairment.
Among participants with very high levels of the biomarker, researchers estimated a 38% risk of cognitive impairment within five years.
The estimated risk increased to 78% over ten years, although researchers emphasized that this longer-term projection was based on substantially fewer observations and should therefore be interpreted cautiously.
During the study, 478 participants developed cognitive impairment. Higher baseline p-tau217 levels were also associated with faster rates of cognitive decline.
Importantly, the biomarker provided additional information about future cognitive risk beyond established factors, including genetic susceptibility and amyloid-related findings from brain imaging.
These results suggest that blood-based biomarkers may become valuable tools for improving risk assessment and identifying individuals who could benefit from participation in early intervention research.
Implications for Alzheimer’s Research and Prevention
Early identification of individuals at increased risk is becoming an important focus of Alzheimer’s research.
Traditional diagnostic approaches often rely on clinical assessments, brain imaging, or specialized laboratory testing. Blood-based biomarkers offer the potential for a less invasive and more accessible approach to assessing biological changes associated with the disease.
However, researchers emphasize that the findings do not establish a blood test capable of predicting with certainty whether an individual will develop Alzheimer’s disease.
The study assessed progression to cognitive impairment, which does not necessarily mean that every affected participant developed Alzheimer’s dementia.
Furthermore, routine p-tau217 testing is not currently recommended for cognitively healthy individuals solely to predict their future risk. Additional studies involving broader populations are needed to establish the clinical reliability and appropriate use of such tests.
A New Direction in Neurological Healthcare
The findings highlight the growing importance of biomarker research in the future of neurological medicine.
As scientists continue to investigate the biological processes underlying Alzheimer’s disease, blood-based technologies may support more personalized research strategies, earlier identification of high-risk populations, and the development of preventive clinical trials.
Although further research is essential, this international study represents meaningful progress toward understanding how Alzheimer’s-related cognitive changes may be anticipated years before symptoms become apparent.
Scientific Source: JAMA (2026)
Study: Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment
DOI: 10.1001/jama.2026.12556
